Dr. Mostaghel [Genentech Investigator] is defining key mechanisms underlying resistance of prostate cancer to hormone treatment.  Suppression of the hormone testosterone is currently the most effective treatment for advanced prostate cancer; however, tumors frequently develop resistance to this therapy.  The Continuation Grant will enable her to continue developing novel treatments for prostate cancer that can be rapidly moved into the clinic.

Dr. Mostaghel works under the mentorship of Peter S. Nelson, MD, at the Fred Hutchinson Cancer Research Center, Seattle, Washington.

 

 

Recent Discoveries:

• March 16, 2009 > Gene expression signature discovered for metastatic prostate cancer

---

Project Title: "Defining and exploiting molecular mechanisms of androgen-metabolism for prostate cancer therapy"

Institution: Fred Hutchinson Cancer Research Center

Sponsor(s) / Mentor(s): Peter S. Nelson, MD

Cancer Type: Prostate

Research Area: Experimental Therapeutics